VivoSeq
Neurology

Relapsing Multiple Sclerosis

8

Pipeline Programs↗

8

Active Trials↗

5

Companies Involved↗

Relapsing Multiple Sclerosis is an early-stage landscape with 8 programs across 5 companies. The most active players are Eli Lilly, Sanofi, Novartis. 1 therapy is approved with 4 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

38/100

Pipeline Velocity

15/100

Mech. Concentration

25/100

Completion Rate

0/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Eli Lilly logo

Eli Lilly

1 program

Phase 3Sanofi logo

Sanofi

1 program

Phase 3Novartis logo

Novartis

3 programs

Phase 3Roche logo

Roche

2 programs

ApprovedT

TG Therapeutics, Inc.

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

7programs
Small molecule457%
Monoclonal antibody229%
Cell therapy114%

Modality classified for 78% of 9 pipeline programs.

Analysis

Trial Status

9

clinical trials

Recruiting5 · 56%
Active, not recruiting3 · 33%
Withdrawn1 · 11%

Clinical Trials

Trial Activity

9 trials

An Open-label, Single-arm Study to Evaluate Pharmacokinetics, Pharmacodynamic Effects, Safety and Tolerability of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis
Recruiting·Roche logoRoche·Phase 2·NCT07161258·12 enrolled
Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS)
Recruiting·TTG Therapeutics, Inc.·Preclinical·NCT07220252·240 enrolled
Ofatumumab in Portuguese Multiple Sclerosis Patients - an Observational Study
Recruiting·Novartis logoNovartis·N/A·NCT05809986·174 enrolled
A Non-interventional Study Evaluating Injectable Treatments (Ofatumumab, Glatiramer Acetate and Interferon β1) and Oral Treatments (Teriflunomide, Dimethyl Fumarate and Diroximel Fumarate) in Patients With Relapsing Multiple Sclerosis [AIOLOS]
Recruiting·Novartis logoNovartis·N/A·NCT05344469·800 enrolled
A Randomized, Open-label, Parallel-group, Non-inferiority Study Comparing Efficacy, Safety, and Tolerability of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis, Followed by Open-label Treatment With Remibrutinib
Recruiting·Novartis logoNovartis·Phase 3·NCT06846281·360 enrolled
A Multicenter, Open-label, Single-arm Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Chinese Patients With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis
Active, not recruiting·Roche logoRoche·Approved·NCT07483450·60 enrolled
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib
Active, not recruiting·Novartis logoNovartis·Phase 3·NCT05156281·1,007 enrolled
A Phase III Multicenter Randomized, Double-blind, Double-dummy, Parallel-group Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Adult Patients With Relapsing Multiple Sclerosis
Active, not recruiting·Roche logoRoche·Phase 3·NCT04586023·751 enrolled
RESET-MS: A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Participants With Multiple Sclerosis
Withdrawn·CCabaletta Bio·Preclinical·NCT07006805

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)